In our study, clinical pathological tumor types, age, tumor location, histological grade, lymph node metastasis, and molecular phenotype expression (ER, PR, HER-2, Ki-67, CK5/6, E-cad, P63, and P120) for breast cancer patients were compared across the subgroups to discuss in detail the molecular phenotypes and clinical characteristics of CHBC compared to other types of breast cancer. This evidence concerns the gene KRT5 and breast cancer.